Pierre Lamond

All filings by Pierre Lamond on record concern IRulya Therapeutics Inc. We count 3 filings, every one of them for a trade on 13 May 2019.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

On 13 May 2019 came the latest disclosure, a transaction in IRulya Therapeutics Inc. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.